Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients

Yoichiro Natori; Eric Martin; Adela Mattiazzi; Leopoldo Arosemena; George William Burke; Mrudula R Munagala; Suresh Manickavel; Katherine Sota; Suresh Pallikkuth; Jessie Chen; Julia Bini; Jacques Simkins; Shweta Anjan; Rodrigo M Vianna; Giselle Guerra

doi:10.1016/j.imlet.2024.106968

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients

Immunol Lett. 2025 Jan 9:106968. doi: 10.1016/j.imlet.2024.106968. Online ahead of print.

Authors

Affiliations

¹ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Infectious Disease, University of Miami Miller School of Medicine Miami, FL, USA.
² Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Hepatology, University of Miami Miller School of Medicine Miami, FL, USA.
³ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine Miami, FL, USA.
⁴ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Surgery, University of Miami Miller School of Medicine.
⁵ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Cardiology, University of Miami Miller School of Medicine Miami, FL, USA.
⁶ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Pulmonology, University of Miami Miller School of Medicine Miami, FL, USA.
⁷ Miami Transplant Institute, Jackson Health System, Miami, FL, USA.
⁸ Department of Medicine, Division of Microbiology, University of Miami Miller School of Medicine Miami, FL, USA.
⁹ Department of Medicine, University of Miami Miller School of Medicine Miami.
¹⁰ Miami Transplant Institute, Jackson Health System, Miami, FL, USA; Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine Miami, FL, USA. Electronic address: [email protected].

PMID: 39798807
DOI: 10.1016/j.imlet.2024.106968

Abstract

Introduction: In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown.

Methods: We conducted a post-hoc analysis of a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs JNJ-78436735 as the third dose after two doses of BNT162b2 in adult SOT recipients with active graft to compare long-term immunogenicity.

Results: Forty-one recipients were analyzed. Median IgG levels against SARS-CoV-2 at 6 months were 53,747 (range 949 - 657,558) and 7,632 (range 642 - 672,000) AU/ml for BNT162b2 vs JNJ-78436735, respectively (p=0.017). The median geometric mean fold increase ratio at 6 months was 37.2 (0.12-618.5) and 4.30 (0.1-204.2) for BNT162b2 vs JNJ-78436735, respectively (p<0.05). After two doses of BNT162b2, homologous approach with BNT162b2 achieved a superior immunogenicity compared to heterologous approach with JNJ-78436735.

Conclusion: In this post hoc analysis, we report durability of specific IgG between two vaccine strategies and found no statistically significant difference between two groups. (Clinical Trial Registry: NCT05047640).

Keywords: COVID-19; heterologous; randomized controlled trial; solid organ transplant; vaccine.

Associated data

ClinicalTrials.gov/NCT05047640